#ThinkSabio Latest News
NOVO NORDISK – TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING A STATISTICALLY SIGNIFICANT AND SUPERIOR WEIGHT LOSS AT WEEK 72 WITH SEMAGLUTIDE 7.2 MG VERSUS PLACEBO.
NOVO NORDISK – TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING A STATISTICALLY SIGNIFICANT AND SUPERIOR WEIGHT LOSS AT WEEK 72 WITH SEMAGLUTIDE 7.2 MG VERSUS PLACEBO.
